Acrobat Interim Results: Peripheral Blood-Based Alloheme Test Enables Robust Relapse Surveillance in Post-HCT AML and MDS Patients

Key Points

• The alloheme test enables effective relapse surveillance for patients with AML and MDS after HCT.
• Interim findings reveal a strong predictive capability in detecting relapses, enhancing patient management.
• Observational analysis involved post-HCT patients, focusing on both AML and MDS for relapse tracking.
• Effective relapse monitoring could improve treatment outcomes, with further validation needed in larger cohorts.